Trade DexCom, Inc. - DXCM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.15 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Dexcom Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 116.11 |
Open* | 116.26 |
1-Year Change* | 5.39% |
Day's Range* | 114.98 - 116.26 |
52 wk Range | 74.75-139.55 |
Average Volume (10 days) | 4.70M |
Average Volume (3 months) | 111.72M |
Market Cap | 42.10B |
P/E Ratio | 123.40 |
Shares Outstanding | 386.37M |
Revenue | 3.40B |
EPS | 0.88 |
Dividend (Yield %) | N/A |
Beta | 1.18 |
Next Earnings Date | Feb 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 30, 2023 | 115.48 | -0.61 | -0.53% | 116.09 | 117.10 | 114.63 |
Nov 29, 2023 | 116.11 | 3.32 | 2.94% | 112.79 | 117.15 | 112.79 |
Nov 28, 2023 | 112.10 | -0.92 | -0.81% | 113.02 | 113.53 | 111.05 |
Nov 27, 2023 | 113.84 | 1.90 | 1.70% | 111.94 | 114.96 | 111.94 |
Nov 24, 2023 | 112.84 | 2.36 | 2.14% | 110.48 | 113.70 | 110.06 |
Nov 22, 2023 | 110.72 | 1.27 | 1.16% | 109.45 | 111.95 | 109.04 |
Nov 21, 2023 | 108.85 | 0.14 | 0.13% | 108.71 | 109.54 | 107.40 |
Nov 20, 2023 | 108.87 | 4.82 | 4.63% | 104.05 | 109.09 | 104.05 |
Nov 17, 2023 | 104.90 | 0.40 | 0.38% | 104.50 | 106.62 | 103.82 |
Nov 16, 2023 | 104.70 | 2.76 | 2.71% | 101.94 | 105.12 | 101.94 |
Nov 15, 2023 | 102.02 | 0.82 | 0.81% | 101.20 | 104.06 | 100.69 |
Nov 14, 2023 | 101.27 | 1.78 | 1.79% | 99.49 | 103.70 | 99.06 |
Nov 13, 2023 | 98.27 | 1.10 | 1.13% | 97.17 | 100.39 | 94.49 |
Nov 10, 2023 | 93.99 | 1.00 | 1.08% | 92.99 | 94.97 | 91.38 |
Nov 9, 2023 | 92.30 | 0.03 | 0.03% | 92.27 | 95.09 | 91.61 |
Nov 8, 2023 | 92.68 | -2.57 | -2.70% | 95.25 | 95.25 | 91.36 |
Nov 7, 2023 | 95.14 | 0.02 | 0.02% | 95.12 | 97.45 | 94.91 |
Nov 6, 2023 | 94.75 | -2.68 | -2.75% | 97.43 | 98.75 | 94.26 |
Nov 3, 2023 | 97.36 | 0.53 | 0.55% | 96.83 | 98.89 | 95.83 |
Nov 2, 2023 | 93.60 | -1.30 | -1.37% | 94.90 | 95.58 | 91.90 |
DexCom, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Dexcom Inc Earnings Release Q4 2023 Dexcom Inc Earnings ReleaseForecast -Previous - |
Thursday, April 25, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Dexcom Inc Earnings Release Q1 2024 Dexcom Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2909.8 | 2448.5 | 1926.7 | 1476 | 1031.6 |
Revenue | 2909.8 | 2448.5 | 1926.7 | 1476 | 1031.6 |
Cost of Revenue, Total | 1012.8 | 739.9 | 622.2 | 530.4 | 367.7 |
Gross Profit | 1897 | 1708.6 | 1304.5 | 945.6 | 663.9 |
Total Operating Expense | 2518.6 | 2182.8 | 1627.2 | 1333.7 | 1217.9 |
Selling/General/Admin. Expenses, Total | 1000.2 | 806.8 | 618.2 | 515.7 | 432.8 |
Research & Development | 484.2 | 604.2 | 359.9 | 273.5 | 417.4 |
Operating Income | 391.2 | 265.7 | 299.5 | 142.3 | -186.3 |
Interest Income (Expense), Net Non-Operating | -0.4 | -8.9 | -1.6 | -38.1 | 59.8 |
Other, Net | |||||
Net Income Before Taxes | 390.8 | 256.8 | 297.9 | 104.2 | -126.5 |
Net Income After Taxes | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Net Income Before Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Net Income | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Income Available to Common Excl. Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Income Available to Common Incl. Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Diluted Net Income | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Diluted Weighted Average Shares | 427.5 | 428.8 | 420.4 | 369.2 | 352.8 |
Diluted EPS Excluding Extraordinary Items | 0.79813 | 0.50583 | 1.30756 | 0.27384 | -0.36139 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 0.83101 | 0.60964 | 1.36632 | 0.33848 | -0.35145 |
Total Extraordinary Items | 0 | 0.4 | |||
Unusual Expense (Income) | 13.9 | 28.2 | 24.4 | 14.1 | |
Depreciation / Amortization | 7.5 | 3.7 | 2.5 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 975 | 871.3 | 741.5 | 815.2 | 769.6 |
Revenue | 975 | 871.3 | 741.5 | 815.2 | 769.6 |
Cost of Revenue, Total | 351.7 | 324.9 | 278.9 | 260 | 275.4 |
Gross Profit | 623.3 | 546.4 | 462.6 | 555.2 | 494.2 |
Total Operating Expense | 769.5 | 743.2 | 694.3 | 689.8 | 622.1 |
Selling/General/Admin. Expenses, Total | 284.7 | 297.3 | 294.6 | 297.8 | 234.6 |
Research & Development | 131.4 | 119.3 | 119 | 116.3 | 110.3 |
Operating Income | 205.5 | 128.1 | 47.2 | 125.4 | 147.5 |
Interest Income (Expense), Net Non-Operating | 1 | 31.2 | 17.3 | 7.8 | -1.3 |
Net Income Before Taxes | 240.4 | 159.3 | 64.5 | 133.2 | 146.2 |
Net Income After Taxes | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Net Income Before Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Net Income | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Income Available to Common Excl. Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Income Available to Common Incl. Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Diluted Net Income | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Diluted Weighted Average Shares | 426.8 | 431.5 | 418.5 | 426 | 425.8 |
Diluted EPS Excluding Extraordinary Items | 0.2828 | 0.2686 | 0.11613 | 0.21549 | 0.23767 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.2828 | 0.2686 | 0.11613 | 0.23798 | 0.23767 |
Unusual Expense (Income) | 13.9 | ||||
Depreciation / Amortization | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 |
Other, Net | 33.9 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 3668.8 | 3684.4 | 3424.8 | 1969.4 | 1699.5 |
Cash and Short Term Investments | 2456.2 | 2731.2 | 2707.7 | 1533.3 | 1385.6 |
Cash & Equivalents | 642.3 | 1052.6 | 817.6 | 446.2 | 1137 |
Short Term Investments | 1813.9 | 1678.6 | 1890.1 | 1087.1 | 248.6 |
Total Receivables, Net | 713.3 | 514.3 | 428.5 | 286.3 | 226.7 |
Accounts Receivable - Trade, Net | 713.3 | 514.3 | 428.5 | 286.3 | 226.7 |
Total Inventory | 306.7 | 357.3 | 234.7 | 119.8 | 70.7 |
Prepaid Expenses | 192.6 | 81.6 | 53.9 | 30 | 16.5 |
Total Assets | 5391.7 | 4933.3 | 4290.5 | 2395 | 1916 |
Property/Plant/Equipment, Total - Net | 1135.6 | 889.9 | 608.6 | 392.8 | 183.1 |
Property/Plant/Equipment, Total - Gross | 1498.8 | 1121.4 | 762.8 | 497.8 | 262.9 |
Accumulated Depreciation, Total | -363.2 | -231.5 | -154.2 | -105 | -79.8 |
Goodwill, Net | 25.7 | 26.5 | 19.3 | 18.6 | 18.7 |
Intangibles, Net | 173.3 | 31.5 | |||
Other Long Term Assets, Total | 388.3 | 301 | 237.8 | 14.2 | 14.7 |
Total Current Liabilities | 1839.3 | 720.8 | 614.1 | 360.2 | 222.4 |
Accounts Payable | 237.9 | 189.4 | 163.3 | 102.3 | 75.5 |
Accrued Expenses | 814.5 | 514.3 | 439.8 | 255.6 | 144 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 776.8 | 8.8 | 0.6 | ||
Other Current Liabilities, Total | 10.1 | 17.1 | 2.2 | 1.7 | 2.9 |
Total Liabilities | 3259.9 | 2891.2 | 2464 | 1512.4 | 1252.7 |
Total Long Term Debt | 1257.3 | 2038.8 | 1721.2 | 1074.1 | 1017.6 |
Long Term Debt | 1197.7 | 1981.8 | 1667.2 | 1059.7 | 1010.3 |
Capital Lease Obligations | 59.6 | 57 | 54 | 14.4 | 7.3 |
Other Liabilities, Total | 158.4 | 125.7 | 128.7 | 78.1 | 12.7 |
Total Equity | 2131.8 | 2042.1 | 1826.5 | 882.6 | 663.3 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 2258.1 | 2109 | 2125.3 | 1675.9 | 1560.6 |
Retained Earnings (Accumulated Deficit) | 479.9 | 138.7 | -202.1 | -695.7 | -798.9 |
Other Equity, Total | -11.6 | 0.5 | 3.2 | 2.3 | 1.5 |
Total Liabilities & Shareholders’ Equity | 5391.7 | 4933.3 | 4290.5 | 2395 | 1916 |
Total Common Shares Outstanding | 386.3 | 388 | 384.4 | 366.4 | 360 |
Treasury Stock - Common | -595 | -206.2 | -100 | -100 | -100 |
Deferred Income Tax | 4.9 | 5.9 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 4698.4 | 5002.9 | 3767.4 | 3668.8 | 3398.5 |
Cash and Short Term Investments | 3240.3 | 3636.2 | 2567 | 2456.2 | 2371.9 |
Cash & Equivalents | 643.7 | 1194.9 | 623.2 | 642.3 | 698.1 |
Short Term Investments | 2596.6 | 2441.3 | 1943.8 | 1813.9 | 1673.8 |
Total Receivables, Net | 785.7 | 755.6 | 652.5 | 713.3 | 564.1 |
Accounts Receivable - Trade, Net | 785.7 | 750.6 | 636.8 | 713.3 | 564.1 |
Total Inventory | 498.6 | 421.1 | 366 | 306.7 | 311 |
Prepaid Expenses | 173.8 | 190 | 181.9 | 192.6 | 151.5 |
Total Assets | 6596.2 | 6820.7 | 5515.9 | 5391.7 | 4899.2 |
Property/Plant/Equipment, Total - Net | 1152.3 | 1153.9 | 1153.5 | 1135.6 | 1075.6 |
Property/Plant/Equipment, Total - Gross | 1618.6 | 1582.2 | 1548 | 1498.8 | 1414.1 |
Accumulated Depreciation, Total | -466.3 | -428.3 | -394.5 | -363.2 | -338.5 |
Goodwill, Net | 25.3 | 25.8 | 25.7 | 25.7 | 24.7 |
Other Long Term Assets, Total | 575.7 | 483.9 | 405.7 | 388.3 | 376 |
Total Current Liabilities | 1678.6 | 2069.7 | 1865 | 1839.3 | 900.5 |
Accounts Payable | 242.4 | 269.1 | 266.2 | 237.9 | 198.1 |
Accrued Expenses | 1303 | 1017.8 | 816 | 818.7 | 699.7 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 9 | 9 | 9.6 | 10.1 | 2.7 |
Total Liabilities | 4328.3 | 4720.3 | 3282.9 | 3259.9 | 3074.7 |
Total Long Term Debt | 2490.3 | 2489.1 | 1257.7 | 1257.3 | 2029.2 |
Long Term Debt | 2432.4 | 2430.6 | 1198.5 | 1197.7 | 1968.8 |
Capital Lease Obligations | 57.9 | 58.5 | 59.2 | 59.6 | 60.4 |
Other Liabilities, Total | 154.8 | 156.7 | 155.4 | 158.4 | 139.7 |
Total Equity | 2267.9 | 2100.4 | 2233 | 2131.8 | 1824.5 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
Additional Paid-In Capital | 3618 | 2269 | 2305.6 | 2258.1 | 2072.1 |
Retained Earnings (Accumulated Deficit) | 765.1 | 644.4 | 528.5 | 479.9 | 388.1 |
Treasury Stock - Common | -2080 | -784.1 | -595 | -595 | -595 |
Other Equity, Total | -35.6 | -29.3 | -6.5 | -11.6 | -41.1 |
Total Liabilities & Shareholders’ Equity | 6596.2 | 6820.7 | 5515.9 | 5391.7 | 4899.2 |
Total Common Shares Outstanding | 386.4 | 386.1 | 387.6 | 386.3 | 386.2 |
Intangibles, Net | 144.5 | 154.2 | 163.6 | 173.3 | 24.4 |
Deferred Income Tax | 4.6 | 4.8 | 4.8 | 4.9 | 5.3 |
Current Port. of LT Debt/Capital Leases | 124.2 | 773.8 | 773.2 | 772.6 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 341.2 | 154.7 | 493.6 | 101.1 | -127.1 |
Cash From Operating Activities | 669.5 | 442.5 | 475.6 | 314.5 | 123.2 |
Cash From Operating Activities | 155.9 | 102 | 67.1 | 48.7 | 29.1 |
Non-Cash Items | 167.3 | 322.7 | 213 | 158.6 | 262.1 |
Cash Taxes Paid | 114.2 | 16.8 | 3.6 | 4.8 | 2.3 |
Cash Interest Paid | 12.2 | 11.6 | 10.6 | 10.4 | 3.6 |
Changes in Working Capital | 26.7 | -132 | -20.8 | 6.1 | -40.9 |
Cash From Investing Activities | -521.5 | -216.1 | -1018 | -1015.2 | -139.8 |
Capital Expenditures | -364.8 | -389.2 | -199 | -180 | -67.1 |
Other Investing Cash Flow Items, Total | -156.7 | 173.1 | -819 | -835.2 | -72.7 |
Cash From Financing Activities | -552.5 | 10.4 | 912.1 | 10.7 | 710.4 |
Issuance (Retirement) of Stock, Net | -535.2 | 20.3 | 15.3 | 11.9 | 94.6 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 906.2 | 0 | 617.7 |
Net Change in Cash | -410.3 | 235.4 | 371.8 | -690.7 | 695.6 |
Foreign Exchange Effects | -5.8 | -1.4 | 2.1 | -0.7 | 1.8 |
Financing Cash Flow Items | -17.3 | -9.9 | -9.4 | -1.2 | -1.9 |
Deferred Taxes | -21.6 | -4.9 | -277.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 48.6 | 341.2 | 249.4 | 148.2 | 97.3 |
Cash From Operating Activities | 155.4 | 669.5 | 537 | 243.8 | 71 |
Cash From Operating Activities | 41.6 | 155.9 | 119.6 | 80.4 | 36.8 |
Deferred Taxes | -9.3 | -21.6 | -53.6 | -19.8 | 0.1 |
Non-Cash Items | 23 | 167.3 | 128.9 | 80.7 | 34.3 |
Changes in Working Capital | 51.5 | 26.7 | 92.7 | -45.7 | -97.5 |
Cash From Investing Activities | -186.7 | -521.5 | -327.4 | -556.7 | -411.8 |
Capital Expenditures | -74.7 | -364.8 | -301.3 | -193.1 | -101.6 |
Other Investing Cash Flow Items, Total | -112 | -156.7 | -26.1 | -363.6 | -310.2 |
Cash From Financing Activities | 11.2 | -552.5 | -551.5 | 1 | 5.3 |
Financing Cash Flow Items | -1.1 | -17.3 | -16.3 | -9.1 | -4.8 |
Issuance (Retirement) of Stock, Net | 12.3 | -535.2 | -535.2 | 10.1 | 10.1 |
Foreign Exchange Effects | 1.1 | -5.8 | -12.6 | -5.3 | -1 |
Net Change in Cash | -19 | -410.3 | -354.5 | -317.2 | -336.5 |
Issuance (Retirement) of Debt, Net | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 11.4173 | 44113549 | 184884 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5734 | 21534123 | 434245 | 2023-06-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 4.3283 | 16723298 | -434201 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.2816 | 16543092 | 399376 | 2023-06-30 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3913 | 13103127 | -635841 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.6614 | 10282913 | -185843 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 2.5805 | 9970251 | 1766071 | 2023-06-30 | LOW |
Capital Research Global Investors | Investment Advisor | 2.3595 | 9116546 | -158069 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.2148 | 8557578 | 274915 | 2023-06-30 | LOW |
Nuveen LLC | Pension Fund | 1.9057 | 7363058 | 54892 | 2023-06-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.8848 | 7282187 | 17192 | 2023-06-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.7102 | 6607873 | 38672 | 2023-09-30 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.3341 | 5154492 | 679071 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.2821 | 4953819 | 768128 | 2023-06-30 | LOW |
William Blair & Company, L.L.C. (Research) | Research Firm | 1.1475 | 4433499 | 77048 | 2023-06-30 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 1.1266 | 4352783 | 173122 | 2023-06-30 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 1.0522 | 4065548 | -56084 | 2023-06-30 | LOW |
Capital World Investors | Investment Advisor | 1.0018 | 3870567 | 124197 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9631 | 3721104 | 403408 | 2022-12-31 | LOW |
Macquarie Investment Management | Investment Advisor | 0.8067 | 3116766 | -168810 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
DexCom Company profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.Industry: | Medical Equipment, Supplies & Distribution (NEC) |
6340 Sequence Dr
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com